---
figid: PMC4700229__tlcr-04-06-752-f1
figtitle: Interactions between immunotherapy and targeted therapy
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4700229
filename: tlcr-04-06-752-f1.jpg
figlink: /pmc/articles/PMC4700229/figure/f1/
number: F1
caption: Interactions between immunotherapy and targeted therapy. T-cell activation
  is a consequence of two simultaneous processes, the expression of protein B7 and
  antigen presentation by antigen presenting cells (APCs) to T-cell receptor. Mitogen-activated
  protein kinase (MAPK) signaling pathway is responsible for differentiation, proliferation,
  and survival of the cells. Mutations on particular stages of the pathway lead to
  uncontrolled enhancements of these processes. The abrogation of the MAPK cascade
  causes cell death and the inhibition of activated T-cells occurs as a result of
  the expression of CTLA-4 and PD-1 receptor on T-cells’ surface. The combination
  of both theoretically improves treatment success.
papertitle: 'Immunotherapy meets targeted therapy: will this team end the war against
  cancer?.'
reftext: Daniela Morales-Espinosa, et al. Transl Lung Cancer Res. 2015 Dec;4(6):752-755.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9665157
figid_alias: PMC4700229__F1
figtype: Figure
redirect_from: /figures/PMC4700229__F1
ndex: 5b6aa1eb-ded0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4700229__tlcr-04-06-752-f1.html
  '@type': Dataset
  description: Interactions between immunotherapy and targeted therapy. T-cell activation
    is a consequence of two simultaneous processes, the expression of protein B7 and
    antigen presentation by antigen presenting cells (APCs) to T-cell receptor. Mitogen-activated
    protein kinase (MAPK) signaling pathway is responsible for differentiation, proliferation,
    and survival of the cells. Mutations on particular stages of the pathway lead
    to uncontrolled enhancements of these processes. The abrogation of the MAPK cascade
    causes cell death and the inhibition of activated T-cells occurs as a result of
    the expression of CTLA-4 and PD-1 receptor on T-cells’ surface. The combination
    of both theoretically improves treatment success.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Apc
  - Apc2
  - Axn
  - Fs(3)Apc
  - btl
  - htl
  - Egfr
  - Shc
  - drk
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - Mtk
  - Akt
  - Erk7
  - rl
  - Mtor
  - Tor
  - APC
  - PROC
  - CD80
  - CD86
  - CTLA4
  - CD274
  - PDCD1LG2
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - PDGFRB
  - PDGFRA
  - EGFR
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - Selumetinib
  - Dabrafenib
  - Cobimetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
